Cynomolgus monkey only (fertility in mice with surrogate antibody)
“General toxicology studies, the embryo-fetal developmental study, and the enhanced pre- and post-natal developmental study (ePPND) were conducted in the cynomolgus monkey, a pharmacologically relevant species.”
✓ VerifiedFDA pharmacology/toxicology review, p. 7Source ↗
Why that species
Neutralizes human and non-human primate IL-6; does not inhibit mouse, rat, dog, pig or guinea pig IL-6
“Siltuximab binds to and neutralizes human and non-human primate IL-6 but does not inhibit mouse, rat, dog, pig or guinea pig IL-6. Therefore, the cynomolgus monkey was selected as a pharmacologically relevant species for the toxicology and pharmacokinetics evaluation of siltuximab.”
Yes: rat anti-mouse IL-6 mAb (CNTO 345) for mouse fertility studies; humanized siltuximab variant (CNTO 136) for monkey ePPND
“A fertility study was conducted with a rat anti-mouse IL6 mAb (CNTO 345) in mice and an enhanced pre- and post-natal development (ePPND) study was conducted with a humanized version of siltuximab (CNTO 136) in cynomolgus monkeys.”
✓ VerifiedFDA pharmacology/toxicology review, p. 16Source ↗